Cor Vasa 2023, 65(6):827-831 | DOI: 10.33678/cor.2023.066
(Inclisiran - the first experiences)
- I. interní klinika - kardiologická, Lékařská fakulta Univerzity Palackého v Olomouci a Fakultní nemocnice Olomouc, Olomouc
We present our first experience with the use of new parenteral hypolipidemic therapy in clinical practice. Our set of patients was started on hypolipidemic therapy with inclisiran and was followed by measuring the lipid spectrum parameters from December 2021 to March 2023. During this follow-up, hypolipidemic therapy with inclisiran proved to be effective and safe with good adherence to therapy.
Keywords: Atherosclerotic cardiovascular disease, Cardiovascular risk, Familial hypercholesterolemia, Inclisiran, Hypolipidemic therapy
Received: August 14, 2023; Revised: August 14, 2023; Accepted: August 20, 2023; Prepublished online: June 2, 2012; Published: December 22, 2023 Show citation
References
- Khvorova A. Oligonucleotide Therapeutics - A New Class of Cholesterol-Lowering Drugs. N Engl J Med 2017;376:4-7.
Go to original source... 
Go to PubMed... - Blaha V. Atherosclerotic cardiovascular diseases and clinical significance of treatment with inclisiran. Klin Farmakol Farm 2021;35:69-73. Go to original source...
- Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020;382:1520-1530. Go to original source... Go to PubMed...
- A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease (ORION-4). Dostupné z: https://clinicaltrials.gov/ct2/show/NCt03705234. Navštíveno: 3. 12. 2023
- Informace VZP o úhradách LEQVIO ze dne 2. 5. 2023 - Sdružení Ambulantních Specialistů (sasp.cz). Dostupné na https://www.sasp.cz/informace-vzp-o-uhradach-leqvio-ze-dne-2-5-2023. Navštíveno: 3. 12. 2023
- SPC Leqvio. Dostupné na: https://www.ema.europa.eu/en/documents/product-information/leqvio-epar-product-information_cs.pdf. Navštíveno: 3. 12. 2023
- Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017;38:2459-2472. Go to original source... Go to PubMed...
- Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41:111-188. Go to original source... Go to PubMed...
- Vrablík M, Piťha J, Bláha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. AtheroRev 2019;4:126-137. Go to original source...
- CCT Collaboration, Baigent T, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta--analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681. Go to original source... Go to PubMed...
- Swiger KJ, Manalac RJ, Blumenthal RS, et al. Statins and Cognition: A Systematic Review and Meta-analysis of Short- and Long-term Cognitive Effects. Mayo Clin Proc 2013;88:1213-1221. Go to original source... Go to PubMed...
- Katzmann JL, Tünnemann-Tarr A, Laufs U. Europäische Leitlinien zu Lipiden 2019. Herz 2019;44:688-695. Go to original source... Go to PubMed...
- Vrablík M. Jak se nám (ne) daří léčit dyslipidemii a proč. AtheroRev 2021;6:46-49.
- Skalická H, Táborský M. Ambulantní kardiologie v praxi: snadno a s přehledem. Praha: Grada Publishing, 2022.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0), which permits non-comercial use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.